CA3217608A1 - Idh mutant inhibitor and use thereof - Google Patents
Idh mutant inhibitor and use thereof Download PDFInfo
- Publication number
- CA3217608A1 CA3217608A1 CA3217608A CA3217608A CA3217608A1 CA 3217608 A1 CA3217608 A1 CA 3217608A1 CA 3217608 A CA3217608 A CA 3217608A CA 3217608 A CA3217608 A CA 3217608A CA 3217608 A1 CA3217608 A1 CA 3217608A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- general formula
- present
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110661394.5 | 2021-06-15 | ||
| CN202110661394 | 2021-06-15 | ||
| PCT/CN2022/099018 WO2022262784A1 (zh) | 2021-06-15 | 2022-06-15 | Idh突变体抑制剂及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217608A1 true CA3217608A1 (en) | 2022-12-22 |
Family
ID=84526875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217608A Pending CA3217608A1 (en) | 2021-06-15 | 2022-06-15 | Idh mutant inhibitor and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240208978A1 (OSRAM) |
| EP (1) | EP4356914A4 (OSRAM) |
| JP (1) | JP2024524933A (OSRAM) |
| KR (1) | KR20240021774A (OSRAM) |
| CN (1) | CN117460512A (OSRAM) |
| AU (1) | AU2022294860A1 (OSRAM) |
| BR (1) | BR112023024454A2 (OSRAM) |
| CA (1) | CA3217608A1 (OSRAM) |
| MX (1) | MX2023013664A (OSRAM) |
| WO (1) | WO2022262784A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035776A1 (en) * | 2024-08-05 | 2026-02-12 | Frontier Medicines Corporation | Pi3k-alpha binding compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| PT3415517T (pt) * | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| KR20150131224A (ko) * | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| MA46064B1 (fr) * | 2014-09-19 | 2020-04-30 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| WO2016171755A1 (en) * | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6473270B2 (ja) * | 2015-07-27 | 2019-02-20 | イーライ リリー アンド カンパニー | ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用 |
| ES2814290T3 (es) | 2016-06-06 | 2021-03-26 | Lilly Co Eli | Inhibidores de IDH1 mutante |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| EP3489230B1 (en) * | 2016-07-21 | 2021-12-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof |
| PH12019501328B1 (en) | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
| WO2020048347A1 (zh) * | 2018-09-04 | 2020-03-12 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| US20200206233A1 (en) * | 2018-12-31 | 2020-07-02 | Integral Biosciences Private Limited | Heterocyclic compounds as mutant idh inhibitors |
-
2022
- 2022-06-15 US US18/287,885 patent/US20240208978A1/en active Pending
- 2022-06-15 CA CA3217608A patent/CA3217608A1/en active Pending
- 2022-06-15 WO PCT/CN2022/099018 patent/WO2022262784A1/zh not_active Ceased
- 2022-06-15 EP EP22824259.0A patent/EP4356914A4/en active Pending
- 2022-06-15 KR KR1020237041032A patent/KR20240021774A/ko active Pending
- 2022-06-15 JP JP2023577688A patent/JP2024524933A/ja active Pending
- 2022-06-15 BR BR112023024454A patent/BR112023024454A2/pt unknown
- 2022-06-15 CN CN202280040684.0A patent/CN117460512A/zh active Pending
- 2022-06-15 MX MX2023013664A patent/MX2023013664A/es unknown
- 2022-06-15 AU AU2022294860A patent/AU2022294860A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023013664A (es) | 2024-01-08 |
| JP2024524933A (ja) | 2024-07-09 |
| AU2022294860A1 (en) | 2024-01-25 |
| BR112023024454A2 (pt) | 2024-02-06 |
| WO2022262784A1 (zh) | 2022-12-22 |
| EP4356914A4 (en) | 2025-01-08 |
| EP4356914A1 (en) | 2024-04-24 |
| US20240208978A1 (en) | 2024-06-27 |
| CN117460512A (zh) | 2024-01-26 |
| KR20240021774A (ko) | 2024-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113717156B (zh) | Egfr抑制剂、其制备方法及用途 | |
| CA3213029A1 (en) | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof | |
| CN113666923A (zh) | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 | |
| WO2021078285A1 (zh) | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 | |
| CN115315427B (zh) | Hpk1抑制剂及其制备方法和用途 | |
| AU2011208139B2 (en) | Piperazine compound having a PGDS inhibitory effect | |
| EP3541822A1 (en) | Magl inhibitors | |
| US20090118303A1 (en) | Serotonin 5-ht3 receptor agonist | |
| JP2023528073A (ja) | Ｇｐｒ６５モジュレーターとしてのｎ－フェニルアミノカルボニル、ピリジノ－、ピリミジノ及びベンゾトロパン | |
| IL296413A (en) | gpr52 modulator compounds | |
| KR20170096599A (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
| JP7761635B6 (ja) | Ｇｐｒ５２モジュレーター化合物 | |
| CN115974855B (zh) | Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途 | |
| EP4356914A1 (en) | Idh mutant inhibitor and use thereof | |
| US11760751B2 (en) | Benzo 2-azaspiro[4.4]nonane compound and use thereof | |
| EP4741391A1 (en) | Nmt inhibitor, and preparation method therefor and use thereof | |
| RU2860311C2 (ru) | Ингибитор мутанта idh и его применение | |
| CN113880804A (zh) | 新型苯并咪唑化合物 | |
| US12559505B2 (en) | IDH mutant inhibitor and use thereof | |
| CN117986269A (zh) | 喜树碱衍生物及其制备方法和应用 | |
| EP4488267A1 (en) | Histamine h3 receptor antagonist and medical use thereof | |
| EP4488263A2 (en) | Phenylurea derivative and pharmaceutical use thereof | |
| WO2022257047A1 (en) | Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof | |
| HK40121805A (en) | Histamine h3 receptor antagonist and medical use thereof | |
| JP2025540298A (ja) | Ｈｄａｃ阻害剤およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250507 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250507 |